Stock Market Update

[BRIEFING.COM] The S&P 500 (-1.1%), Nasdaq Composite (-1.2%), and DJIA (-1.6%) now trade in a relatively steady range shortly after midday. 

Novo Nordisk A/S (NVO 40.10, -7.32, -15.44%) is plunging to multi-year lows after CagriSema failed to meet the primary endpoint in the open-label, head-to-head REDEFINE 4 obesity trial versus Eli Lilly's (LLY 1058.97, +49.45, +4.90%) tirzepatide. The readout is another blow to the obesity and diabetes drugmaker, which is already dealing with U.S. pricing pressure, intensifying competition, and semaglutide patent expirations in some markets, and it comes after November's negative EVOKE Alzheimer's Phase 3 readout and Pfizer's (PFE) win in the Metsera deal.

Specifically, patients treated with CagriSema achieved 23.0% weight loss after 84 weeks, versus 25.5% for tirzepatide, failing to meet the primary endpoint despite a strong absolute weight-loss result.

While 23% weight loss is a strong result in absolute terms, this was a head-to-head trial and a key opportunity for NVO to show CagriSema could compete more directly with LLY's tirzepatide, and it fell short, which explains the sharp sell-off. The issue is less about whether CagriSema works and more about competitive positioning, as LLY's tirzepatide delivered better weight-loss results in the trial and reinforced the current gap between the two. That miss also reflects the broader divergence in momentum, with LLY posting stronger obesity growth while NVO contends with pricing pressure, competition, and recent pipeline setbacks.